Hearing

Publication and Disclosure Issues in Anti-Depressant Pediatric Clinical Trials

Subcommittee on Oversight and Investigations
September 9, 2004
2123 Rayburn House Office Building
11:00 AM

Hearing Webcast: Pending

The hearing will begin at approximately 11:00 AM. The link to the broadcast will become active 10 minutes prior to the start of the hearing. Refresh your browser for the latest information.

Committee web casts require the free Real Player.

Witness List & Prepared Testimony

Panel 1
Dr. Janet Woodcock M.D. Acting Deputy Commissioner for Operations U.S. Food and Drug Administration, Department of Health and Human Services Rockville, MD, 20857	Dr. Ronald N. Marcus M.D. Executive Director Neuroscience Global Clinical Development Pharmaceutical Research Institute Bristol-Myers Squibb Company
Dr. Richard Gorman M.D., FAAP American Academy of Pediatrics	Dr. Lawrence S. Olanoff Executive Vice President Forest Laboratories, Inc.
Dr. David E. Wheadon, M.D. Senior Vice President U.S. Regulatory Affairs GlaxoSmithKline	Mr. Patrick J. Osinski, Esq. Organon USA Inc.
Dr. Cathryn M. Clary M.D. Vice President, U.S. Medical Neuroscience and Customer and Market Development Pfizer Global Pharmaceuticals Pfizer Inc. 235 E 42nd Street New York, NY, 10017	Ms. Caroline Loew, Ph.D. Vice President, Scientific and Regulatory Affairs Pharmaceutical Research and Manufacturers of America

Hearing Transcript: Not Available

The transcript of this hearing should be available within 60-90 days of the conclusion of the hearing. Click here for the latest list of available hearing transcripts..

Available Member Statements

There are no prepared Member Statements currently available.